IBM Faces Analyst Caution Ahead of Quarterly Earnings Report

Analysts lower IBM stock targets on near-term acquisition costs, but maintain neutral ratings as AI bookings surge and a 30% upside consensus remains.

As IBM prepares to release its first-quarter 2026 financial results, two prominent financial institutions have revised their outlooks for the technology giant's stock. BMO Capital and JP Morgan have both reduced their price targets, signaling tempered short-term expectations while maintaining neutral ratings on the shares.

Revised Price Targets Reflect Near-Term Concerns

In adjustments made just prior to the earnings announcement, BMO Capital lowered its target for IBM shares from $350 to $290. JP Morgan followed a similar path, cutting its objective from $317 to $283. The broader analyst community, however, maintains a generally constructive stance. Among 22 market experts covering the stock, nine advocate a strong buy position, while ten recommend holding. The consensus median price target stands at $313.90, suggesting a potential upside of approximately 30% from current trading levels.

For the quarter ending soon, Wall Street anticipates earnings per share of $1.78, which would represent an 11.3% increase compared to the same period last year. It is noteworthy that IBM has surpassed profit expectations in each of the last four reporting periods, a track record that provides context to the recent target reductions.

Acquisition Impact Weighs on Sentiment

A significant factor influencing the cautious analyst mood is IBM's recent strategic move. The company finalized its acquisition of Confluent in March, a transaction valued at $11 billion. Management has indicated that this deal will negatively impact 2026 results by roughly $600 million. Operational synergies, estimated at about $500 million annually, are not expected to be fully realized until 2027.

Strategically, the combination aims to merge Confluent's real-time data streaming capabilities with IBM's artificial intelligence and hybrid cloud platform. The goal is to provide enterprises with an integrated data foundation for AI applications. On the day the acquisition closed, IBM's stock price advanced by 2.8%.

Growth Drivers and Competitive Pressures

On a positive note, IBM has reported generative AI bookings exceeding $12 billion through early 2026. For the full year, the company is targeting consistent revenue growth above five percent, alongside a projected free cash flow of around $15.7 billion. Its software business is expected to expand by approximately ten percent.

Concurrently, the company faces several challenges. The current share price trades about twelve percent below its 200-day moving average of €238.40. Furthermore, analysts project a revenue decline of roughly 1.5% for 2026. This forecast is partly attributed to increasing competition in its legacy COBOL business, fueled by emerging tools like Anthropic's Claude Code.

All eyes are now on the quarterly report scheduled for release after U.S. market close on April 22. The figures will reveal whether IBM's momentum in artificial intelligence can sufficiently offset the short-term costs of integrating Confluent and the prevailing margin pressures.